Cyagen: Cyagen Closes $41 Million Series B to Expand Animal Research Model Business

Cyagen Biosciences Suzhou closed a $41 million Series B financing that it will use to expand its genetically modified rodent business. The round included investments from funds managed by CMS Capital two GF Securities entities and Guanghua Investment. Foun...